Amitriptyline: Independent Evidence on Pain, Migraine, IBS, Risks & Withdrawal
Independent review of amitriptyline: ATLANTIS IBS trial, nerve pain, migraine and depression evidence, overdose and anticholinergic risks, and who funded it.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Independent review of amitriptyline: ATLANTIS IBS trial, nerve pain, migraine and depression evidence, overdose and anticholinergic risks, and who funded it.
Independent review of citalopram for depression and panic: Cipriani 2018 results, QT dose limits for over-65s, side effects, withdrawal and who funded the evidence.
Independent review of fluoxetine (Prozac): NICE, Cochrane and FDA evidence for depression, young people, OCD and bulimia, plus risks and who funded the trials.
Sertraline reviewed: what independent trials show for depression, OCD, PTSD and anxiety, plus side effects, interactions, withdrawal and who funded the evidence.
Escitalopram (Cipralex/Lexapro): what independent trials show for depression and anxiety, side effects, QT dose limits, withdrawal, and who funds the evidence.
Historical fatigue trials are mixed and limited; a small depression comparison found no significant between-group benefit. Preparation-specific traditional use is distinct from proven efficacy, and medication risks remain incompletely defined.
Small Lion’s Mane trials report limited, mixed results with preparation-specific protocols. Positive individual tasks do not establish reliable brain-fog treatment or nerve repair; safety and financial reporting remain incomplete.
Tongkat Ali studies concern particular root extracts. The cited testosterone review reports a positive pooled marker result but high heterogeneity, publication-bias signals and repeated comparisons; normal-testosterone findings are inconclusive. Erectile-function evidence does not establish Tongkat alone. The salivary-hormone stress trial and several underlying trials disclose Biotropics funding and commercial roles. EFSA could not establish safety for the assessed extract, and liver-injury causality and incidence remain uncertain. The cited protocols do not establish a universal safe dose or medicine compatibility.
Saffron trials report uneven mood benefits. Compare outcome scales, product-specific doses, commercial support, safety signals and unresolved evidence limits.
Ashwagandha has short-term stress and sleep findings, but trials do not establish one best form or dose. Review the source-specific funding, liver and thyroid risks, and medicine cautions.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.